Clinical Trials Logo

Hearing Loss Ototoxic clinical trials

View clinical trials related to Hearing Loss Ototoxic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05628233 Recruiting - Clinical trials for Hearing Loss Ototoxic

SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

NOTOXIS
Start date: December 30, 2022
Phase: Phase 2
Study type: Interventional

This study is intended to evaluate the ability of SENS-401 to prevent the ototoxicity induced by cisplatin in subjects with a neoplastic disease. It is a multicenter, randomized, controlled, two-arm, open-label efficacy and safety study in adults with neoplastic disease requiring treatment with cisplatin as part of the chemotherapy protocol plan.

NCT ID: NCT03400709 Completed - Clinical trials for Cisplatin Adverse Reaction

Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

Start date: November 2015
Phase: N/A
Study type: Interventional

Introduction. Cisplatin-induced ototoxicity is a very frequent event and its consequences can cause a lot of deterioration in patients. Early diagnosis is essential because it would allow the appropriate implementation of strategies to reduce its effect. Among these N-acetylcysteine, an antioxidant agent that has shown otoprotective effect. Study design. Randomized, parallel design and placebo controlled clinical trial. Methods. Patients with head and neck cancer who require treatment with cisplatin were enrolled in 2 branches: a control group that receives a placebo and experimental group that receives the drug. High-frequency audiometries (6 - 16 KHz) are performed before, during and after the treatment finalization.